

Short Research Article

Berberine Prevents Bone and Cartilage Destruction and Influences Cell Senescence in Experimental Arthritis

ABSTRACT

Background: Berberine (BB) is a protoberberine alkaloid with a wide spectrum of pharmacological activities considered to be a selective Janus kinase (Jak)3 inhibitor. Nevertheless, the mechanisms of berberine's actions on joint inflammation have not been well clarified.

Aim: This study evaluated the effect of berberine on cartilage and bone destruction, and on generation of senescent cells.

Methodology: The experiments were conducted in a murine model of erosive arthritis induced by intra-articular (i.a.) injection of zymosan (zymosan-induced arthritis, ZIA). Histopathologic changes were evaluated by haematoxylin and eosin (H&E), toluidine blue and Sudan Black B (SBB) staining. Bone marrow (BM) cells were shifted to osteoblast differentiation and alkaline phosphatase (ALP) positive cells were determined together with LP activity in the cell lysates.

Results: Berberine decreased cartilage and bone erosion. The loss of glycosaminoglycans (GAGs) was lower in BB-treated group ($72.0 \pm 2.9\%$ in ZIA mice vs $25.7 \pm 2.2\%$ in BB group). BB inhibited the generation of senescent cells and decreased the ALP activity of these cells (0.550 ± 0.006 for non-arthritic, $1.725.8 \pm 0.110$ for ZIA and 0.750 ± 0.0064 for ZIA+BB).

Conclusion: Berberine showed potential anti-arthritic properties in a model of erosive RA perspective for administration in joint disorders.

Keywords: berberine; zymosan-induced arthritis; synovitis; osteoblasts

1. INTRODUCTION

Rheumatoid arthritis (RA) is a chronic inflammatory joint disease characterized with inflammation of the synovial lining of joints which leads to progressive erosion of bone, in most cases irreversible, loss of function, and disability [1]. Onset of RA can begin at any age but increases with age. Although the prospects for most patients are now optimistic, many still do not respond to current therapies. Accordingly, new therapies are strongly required. Despite the central role of the adaptive immune system in RA pathogenesis, the innate immune system has a key role in this scenario. The underlying disease mechanisms remain unclear but are generally triggered by infections and inflammatory mediators [2]. At the articular borders, in a result of ongoing inflammation the lining layer forms a pannus that invades the adjacent articular cartilage and subchondral bone. Synovial T cells are attracted by chemokines and receive survival signals such as IL-7 and IL-15 [3]. The pannus formation is composed of infiltrating cells, such as monocytes/macrophages, as well as RA synovial fibroblasts. They secrete proinflammatory cytokines and chemokines that perpetuate inflammation. In addition, they release receptor activator of nuclear factor-kappa B ligand (RANKL) and promote osteoclast differentiation, leading to bone destruction [4]. Cartilage undergoes damage by catabolic effects in chondrocytes after their stimulation by cytokines. Proteins from the synovial tissue of RA patients are extensively phosphorylated by intracellular tyrosine kinases, proving the importance of tyrosine kinases in the pathogenesis of RA [5]. Post-transcriptional and post-translational events further regulate mediator production. The janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway has received less attention than other signaling pathways. However, several cytokines implicated in RA pathogenesis, including IL-6, IL-1, and interferons (IFNs), activate the JAK/STAT pathway, moreover STAT3 is constitutively activated in RA [6]. Many drugs are in development to target tyrosine kinases for the treatment of RA. The administration of anti-IL-6 antibody in RA that is predicted to block JAK/STAT activation has shown promising results. Kinase inhibitors might be considered as new therapeutic strategies for RA.

Berberine is a protoberberine alkaloid, isolated from root, rhizome and stem bark of various *Berberis* species. Its beneficial effect is established after application in metabolic disorders [7] related to lowering blood cholesterol, triglycerides and atherogenic apolipoproteins [8]. Berberine is reported to express antiarrhythmic, vasodilator and hypertensive properties [9-10]. The therapeutic dosage is most often 200 mg orally two to four times daily. Side effects are documented at high dosages, including gastrointestinal discomfort, lowered blood pressure or flu-like symptoms. Berberine is considered to be a predominantly selective Jak3 antagonist. Data from kinase assays and protein-compound docking simulation show that berberine blocked Jak3 catalytic activity after binding to the kinase domain of Jak3 [11]. Recent investigations prove that the alkaloid also activates Jak2/STAT3 pathway [12]. In previous investigations we have shown the beneficial effect of berberine in adjuvant-induced arthritis and in autoimmune tubulointerstitial nephritis administered under different schemes [13-14]. We have found that the alkaloid delayed the development of adjuvant arthritis when applied after its onset at a dose of 10 mg/kg. Also, we have established berberine's anti-osteoclastogenic effect *in vitro* [15]. The aim of the present study was to evaluate the effect of berberine on bone and cartilage erosion, and on synovial cell and osteoblast senescence in a mouse model of erosive arthritis induced by intraarticular injection of zymosan.

2. MATERIAL AND METHODS

2.1. Substance and Treatment

Berberine was used as a sulphate [(C₂₀H₁₈NO₄)₂-SO₄·H₂O] dissolved in distilled H₂O and injected intraperitoneally i.p. in a dose of 10 mg/kg every other day from day 0 to day 12 of ZIA. The dose and time schedule of berberine were referenced by previous studies in adjuvant-induced arthritis [13].

2.2. Mice

Balb/c mice (Charles River Laboratories, Wilmington, MA, USA) were maintained at 12/12 light dark cycle in pathogen free conditions and were fed with pelleted food and tap water ad libitum. All experiments were conducted in accordance with the International and National Guidelines for the Care and Use of Laboratory Animals and were approved by the Animal Care Committee at the Institute of Microbiology (Guidelines №352 06.01.2012), Sofia.

2.3. Zymosan-Induced Arthritis (ZIA)

Mice received an intra-articular (i.a.) injection of 180 µg zymosan A from *Saccharomyces cerevisiae* (Sigma-Aldrich, Germany) under brief anaesthesia (sodium pentobarbital 50 mg/kg, i.p) (day 0). Control animals received an i.a. injection of an equal volume of sterile phosphate buffered saline (PBS).

2.4. Histopathologic Examination

Knee joints were dissected at the active phase of ZIA (day 18) and at the late chronic phase (day 56), fixed for 4 days in 10% formalin, decalcified by incubation in 10 % EDTA/0.2% PFA in PBS at 4°C for 20 days and embedded in paraffin. Tissue samples 5 µm thick were dewaxed with xylene, dehydrated until 70% ethanol and stained with haematoxylin and eosin (H&E) for routine histological evaluation. For Sudan Black B (SBB) staining the slides were mounted in saturated 70% ethanol solution for 8 min and then embedded into 50% ethanol, transferred and washed in distilled water. Lipofuscin staining was considered positive when perinuclear and cytoplasmic aggregates of blue-black granules were evident inside the cells. For detection of proteoglycans joint sections were stained with 1% toluidine blue. Toluidine blue-stained sections were examined to measure the areas of total and negatively stained cartilage to show glycosaminoglycan (GAG) distribution and loss. The proportion of damaged cartilage was calculated by dividing the area of negatively stained cartilage by the area of total cartilage. All histologic assessments were performed in a blinded protocol. Images were captured with a coupled device camera and exported to Adobe Photoshop CS6.

82 2.5. Isolation of Bone Marrow Cells and Osteoblast Differentiation

83 Bone marrow was isolated aseptically from long bones of 8-10 weeks healthy mice or from mice at day 7
84 of ZIA. The suspension was gently aspirated to disrupt cell aggregates and after centrifugation cells were
85 resuspended at a concentration of $1 \times 10^6/\text{ml}$ in 24 well plate in minimum essential medium (α -MEM,
86 Sigma Aldrich, Germany), supplemented with 10% heat-inactivated FCS, 2% gentamicin, 100 U/ml
87 penicillin, 100 $\mu\text{g}/\text{ml}$ streptomycin, 50 $\mu\text{g}/\text{ml}$ L-ascorbic acid and 5 mM β -glycerophosphate for 21 days
88 with media change every 3 days.

89 2.6. Alkaline Phosphatase (ALP) Staining and ALP Activity Assays

90 After cell culture, the fixed cells were incubated in 50 mM MgCl_2 and 0.1 M Tris-HCl (pH 7.4) for 30 min.
91 Cells were then stained for alkaline phosphatase with a mixture of 0.1 mg/ml Naphthol ASMX (Sigma-
92 Aldrich) phosphate and 0.6 mg/ml. Fast blue RR salt (Sigma-Aldrich) in 0.2 M Tris-HCl (pH 8.5). An
93 aliquot of cell lysate was added to ALP substrate buffer, containing 2 mg/ml p-nitrophenyl phosphate
94 (Sigma), 0.1 M diethanolamine, 1 mM MgCl_2 , 0.1% Triton X- 100 (pH 9.8), and the mixture was incubated
95 at 37 °C for 30 min. The enzymatic reaction was stopped by the addition of 0.5 M NaOH, and the
96 absorbance was read at 405 nm. A calibration line was constructed from different concentrations of p-
97 nitrophenol.

98 2.7. Statistical Analysis

99 Data represent mean $\pm$ SEM. Statistical significance was assessed using one-way ANOVA, as indicated
100 in the figure legends, considering a P value = .05 as significant.

101 3. RESULTS AND DISCUSSION

102 We aimed to study the effect of berberine on cartilage and bone destruction at different stages of arthritis.
103 At the active phase of ZIA we observed deformation of cartilage surface and degradation with a presence
104 of osteoclasts (Fig. 1 arrow). In the late chronic phase the synovial lesion invaded the adjacent bone and
105 strongly supported osteophyte formation. The administration of berberine had a beneficial effect on the
106 development and progression of ZIA as demonstrated by inhibited cartilage and bone damages and lack
107 of osteophyte and pannus formation although, signs of cartilage hyperplasia were observed at day 56.
108
109
110




Fig. 1. H&E staining of joint sections from healthy mice, mice with ZIA and mice with ZIA treated with berberine (BB) at day 18 and day 56 of arthritis.

Deformation of cartilage surface and degradation with a presence of osteoclasts (oc) was observed in arthritic mice (arrows), cell infiltration (ci), synovial hyperplasia (hp) and panus (p), all inhibited in BB treated mice. n = 7 per group in three separate experiments.

Histopathological data showed significant loss of GAGs already at early phase of ZIA (day 7) while in BB treated mice cartilage was to a great extent preserved (Fig. 2) that corresponded to bone erosion and cell infiltration seen in Fig. 1.




Fig. 2. Berberine (BB) reduced GAG thinning (toluidine blue staining).

*(A) Red arrows indicate destained articular cartilage. (B) Percentage of destained areas showing cartilage loss. n = 5 per group in three separate experiments. *** P = .001.*

The detection of lipofuscin is highly specific for the visualization of senescent cells which are hyper-metabolic and full of lipids in the cytoplasm. The progressive chondrocyte senescence associated with alkaline phosphatase and beta-galactosidase enzyme expression leads to the age related loss of chondrocyte function [16]. By applying the SBB staining we observed that the development of ZIA is attended with the presence of senescent cells in synovium at the acute and chronic phases. While the

senescent process was weakly inhibited by berberine treatment in the acute phase, SBB positive cells were almost absent in the chronic phase (Fig. 3).




Fig. 3. Effect of berberine (BB) treatment on the accumulation of senescent cells in the synovium at day 7 and day 56 of ZIA.

Representative pictures of cells stained with Sudan Black B (SBB). n = 7 per group in three separate experiments.

Bone remodeling is characterized by a sequence of events occurring at bone surfaces, mediated by multicellular units comprised of a specialized group of cells, namely bone-resorbing osteoclasts, bone-forming osteoblasts and their precursors. Normally, the amount of bone removed by osteoclasts is equal to the amount of bone formed by osteoblasts, thus a stable bone mass is maintained. Osteoblasts are mononuclear, not terminally differentiated cells derived from mesenchymal cells. Mineralization of the extracellular matrix is one of the key bone formation markers and is influenced by cytokines. The inhibition of osteoblast differentiation contributes to the development of arthritic bone loss in RA as well as to the markedly diminished capacity of erosions to be restored [17]. Chronic inflammation is associated with aging and is often attributed to the progressive activation of immune cells over time [18-19]. No single marker may define a cell as senescent since none of these markers are exclusive to cellular senescence. Owing to the absence of specific markers, bone marrow mesenchymal cells are usually identified by their ability to form colonies that stain positive for alkaline phosphatase when cultured *in vitro*. In present experiments, BM cells from non-arthritic mice and cells from mice with ZIA were cultivated in a specific medium containing β -glycerophosphate and ascorbic acid thus supporting osteoblast differentiation. After day 14 we registered the start of osteoblast generation and until day 21 we observed a presence of osteoblast nodules. Notably, in cultures of arthritic cells a lot of giant, diffuse,

ALP positive cells were noticed (Fig. 4A, red arrows). These cells expressed high ALP activity pointing on their activated state (Fig. 4B). It is known that senescent cells exhibit a characteristic secretory phenotype involving inflammatory cytokines, growth factors, and matrix-degrading proteases that modulate and alter their local microenvironment. It is of importance that arthritic cells obtained at the active phase of ZIA are predisposed to accelerated senescence. As a consequence, the process of senescence probably leads to apoptosis of osteoblasts and lower capacity of bone remodeling.




Fig. 4. Effect of berberine (BB) treatment on osteoblast ageing.

Bone marrow cells isolated from healthy and arthritic mice at day 18 of ZIA were cultivated in specific medium for 21 days in the presence or absence of 20 μ M BB from day 0 to day 5, and then stained with fast blue. Red arrows indicate senescent ALP positive cells (A). ALP activity is presented in (B). $n = 5$ per group in three separate experiments. *** $P = .001$.

4. CONCLUSION

The present study demonstrated that berberine reduced cartilage and bone destruction through decreased cell infiltration and prevention of GAG loss. The substance inhibited the generation of senescent cells in the synovium thus leading to ameliorated synovitis. Concomitantly, berberine diminished the appearance of senescent cells during osteoblast differentiation in vitro. The effect of the substance can be defined as a long-time since the assessment was done 6 weeks after the last treatment. These findings provide new mechanistic insight into the anti-arthritic effects of berberine and are promising basis for its use in arthritic disorders.

REFERENCES

1. Firestein GS. Evolving concepts of rheumatoid arthritis. *Nature*. 2003;423: 356-361.
2. Araki Y, Mimura T. The Mechanisms Underlying Chronic Inflammation in Rheumatoid Arthritis from the Perspective of the Epigenetic Landscape. *J. Immunol. Res.* 2016;2016: 6290682.
3. Harada S, Yamamura M, Okamoto H et al. Production of interleukin-7 and interleukin-15 by fibroblast-like synoviocytes from patients with rheumatoid arthritis. *Arthritis Rheum.* 1999;42: 1508-1516.
4. Shigeyama Y, Pap T, Kunzler P et al. Expression of osteoclast differentiation factor in rheumatoid arthritis. *Arthritis Rheum.* 2000;43: 2523-2530.
5. D'Aura Swanson C, Paniagua RT, Lindstrom TM et al. Tyrosine kinases as targets for the treatment of rheumatoid arthritis. *Nat. Rev. Rheumatol.* 2009;5: 317-324.
6. Gomez-Puerta JA, Mocsai A. Tyrosine kinase inhibitors for the treatment of rheumatoid arthritis. *Curr. Top. Med. Chem.* 2013;13: 760-773.
7. Zhou Y, Cao S, Wang Y et al. Berberine metabolites could induce low density lipoprotein receptor up-regulation to exert lipid-lowering effects in human hepatoma cells. *Fitoterapia.* 2014;92: 230-237.
8. Pirillo A, Catapano AL. Berberine, a plant alkaloid with lipid- and glucose-lowering properties: From in vitro evidence to clinical studies. *Atherosclerosis.* 2015;243: 449-461.

- 204 9. Al Disi SS, Anwar MA, Eid AH. Anti-hypertensive Herbs and their Mechanisms of Action: Part I.
205 Fron.t Pharmacol. 2015;6: 323.
- 206 10. Suman RK, Borde MK, Mohanty IR et al. Myocardial Salvaging Effects of Berberine in
207 Experimental Diabetes Co-Existing with Myocardial Infarction. J. Clin. Diagn. Res. 2016;10:
208 FF13-18.
- 209 11. Kim BH, Kim M, Yin CH et al. Inhibition of the signalling kinase JAK3 alleviates inflammation in
210 monoarthritic rats. Br. J. Pharmacol. 2011;164: 106-118.
- 211 12. Zhao GL, Yu LM, Gao WL et al. Berberine protects rat heart from ischemia/reperfusion injury via
212 activating JAK2/STAT3 signaling and attenuating endoplasmic reticulum stress. Acta Pharmacol.
213 Sin. 2016;37: 354-367.
- 214 13. Ivanovska N, Philipov S, Hristova M. Influence of berberine on T-cell mediated immunity.
215 Immunopharmacol. Immunotoxicol. 1999;21: 771-786.
- 216 14. Marinova EK, Nikolova DB, Popova DN et al,. Suppression of experimental autoimmune
217 tubulointerstitial nephritis in BALB/c mice by berberine. Immunopharmacology. 2000;48: 9-16.
- 218 15. Ganova P, Gyurkovska V, Doncheva T et al,. Isoquinoline alkaloid berberine acts as an inhibitor
219 of osteoclast differentiation. J. Internat. Res. Med. Pharm. Sci. 2017;11: 131-141.
- 220 16. Sikora E, Arendt T, Bennett M et al,. Impact of cellular senescence signature on ageing research.
221 Ageing Res. Rev. 2011;10: 146-152.
- 222 17. Baum R, Gravalles EM. Bone as a Target Organ in Rheumatic Disease: Impact on Osteoclasts
223 and Osteoblasts. Clin. Rev. Allergy Immunol. 2016;51: 1-15.
- 224 18. Collado M, Blasco MA, Serrano M. Cellular senescence in cancer and aging. Cell. 2007;130: 223-
225 233.
- 226 19. Rodier F, Campisi J. Four faces of cellular senescence. J. Cell Biol. 2011;192: 547-556.

APPENDIX

228